1. Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
   Xinping Cao et al, 2023, Current Treatment Options in Oncology CrossRef
2. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
   Shambavi Richard et al, 2022, BioDrugs CrossRef
3. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
   Xiaomin Zhang et al, 2022, Frontiers in Immunology CrossRef
4. Treatment of multiple myeloma with selinexor: a review
   Qianlei Huang et al, 2024, Therapeutic Advances in Hematology CrossRef
5. Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options
   Raul Del Toro‐Mijares et al, 2023, British Journal of Haematology CrossRef
6. A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
   Di Wang et al, 2023, Journal of Translational Medicine CrossRef
7. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
   Benjamin A Derman et al, 2023, European Journal of Haematology CrossRef
8. Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer
   Jack Fisher et al, 2022, Vaccines CrossRef
9. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
   Jack G. Fisher et al, 2023, Leukemia CrossRef
10. Therapeutic Targeting of Exportin-1 in Childhood Cancer
    Basia Galinski et al, 2021, Cancers CrossRef
11. Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
    Jack G. Fisher et al, 2021, Frontiers in Oncology CrossRef
12. Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
    Adam F. Binder et al, 2023, Frontiers in Immunology CrossRef